The week in pharma: action, reaction and insight – week to September 8, 2023

10 September 2023

By Barbara Obstoj-Cardwell. Editor

Last week, the USA’s Seagen and Danish partner Genmab released positive new Phase III data on their Tivdak in the treatment of cervical cancer. Also, US clinical-stage biotech CymaBay Therapeutics released positive Phase II results for its seladelpar in biliary cholangitis. On the regulatory front, the US Food and Drug Administration (FDA) issued a complete response letter (CRL) on UK pharma major AstraZeneca’s supplemental biologic license application (sBLA) for its rare disease drug Ultomiris. Meantime, US clinical-stage biopharma Nurix Therapeutics revealed a collaboration with Seagen to develop degrader-antibody conjugates for cancer.

Seagen’s Tivdak improves OS in cervical cancer

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK